135 related articles for article (PubMed ID: 25525637)
1. A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
Rabasseda X
Drugs Today (Barc); 2014 Nov; 50(11):763-74. PubMed ID: 25525637
[TBL] [Abstract][Full Text] [Related]
2. A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 - Vienna, Austria).
Rabasseda X
Drugs Today (Barc); 2015 Apr; 51(4):261-71. PubMed ID: 26020068
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease: Advances in Diagnosis, Treatment and Clinical Practice. AASLD Liver Meeting, Boston, November 7-11, 2014].
Pár A
Orv Hetil; 2015 May; 156(21):869-72. PubMed ID: 26038995
[No Abstract] [Full Text] [Related]
4. The Liver Meeting 2016 - American Association for the Study of Liver Diseases, 67th Annual Meeting (November 11-15, 2016 - Boston, Massachusetts, USA).
Künnemann K
Drugs Today (Barc); 2016 Dec; 52(12):673-680. PubMed ID: 28276539
[TBL] [Abstract][Full Text] [Related]
5. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA.
Ndugga N; Lightbourne TG; Javaherian K; Cabezas J; Verma N; Barritt AS; Bataller R
BMJ Open; 2017 Mar; 7(3):e013620. PubMed ID: 28336739
[TBL] [Abstract][Full Text] [Related]
6. The Liver Meeting 2013: a report from the 64th meeting of the American Association for the Study of the Liver (November 1-5, 2013 - Washington, D.C., USA).
Rabasseda X
Drugs Today (Barc); 2013 Dec; 49(12):809-22. PubMed ID: 24524100
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
Piazza NA; Singal AK
Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
[TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
10. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
12. The Liver Meeting Digital Experience 2021.
Thomas H
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):15. PubMed ID: 34895506
[No Abstract] [Full Text] [Related]
13. American Association for the Study of Liver Diseases--53rd Annual Meeting. 1-5 November 2002, Boston, MA, USA.
Levitsky J
IDrugs; 2003 Jan; 6(1):30-3. PubMed ID: 12838972
[No Abstract] [Full Text] [Related]
14. Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.
Boettler T; Moradpour D; Thimme R; Zoulim F
J Hepatol; 2014 Sep; 61(3):696-705. PubMed ID: 24845610
[TBL] [Abstract][Full Text] [Related]
15. [Reversibility of hepatitis B virus-induced liver cirrhosis after prolonged antiviral therapy].
Pérez Roldán F; Vives Domínguez L; González Carro P; Villafáñez García MC; Fernández Acenero MJ; Cuesta Domínguez R; Aoufi Rabih S; Ruíz Carrillo F
Gastroenterol Hepatol; 2010; 33(7):498-503. PubMed ID: 20630622
[TBL] [Abstract][Full Text] [Related]
16. REVIEW- Contemporary evidence on the dynamic role of probiotics in liver diseases.
Ahmed B; Rasul A; Tareen KZ; Hamid Akash MS; Muhammad SA; Irfan M; Abbas K; Qadir MI
Pak J Pharm Sci; 2019 Nov; 32(6):2765-2770. PubMed ID: 31969314
[TBL] [Abstract][Full Text] [Related]
17. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury.
Yamaura Y; Tatsumi N; Takagi S; Tokumitsu S; Fukami T; Tajiri K; Minemura M; Yokoi T; Nakajima M
Clin Biochem; 2017 Dec; 50(18):1034-1039. PubMed ID: 28823616
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Laboratory Tests for Liver Diseases].
Ikeda H
Rinsho Byori; 2014 Nov; 62(11):1065-71. PubMed ID: 27509722
[TBL] [Abstract][Full Text] [Related]
19. Cyclophilin inhibition as potential therapy for liver diseases.
Naoumov NV
J Hepatol; 2014 Nov; 61(5):1166-74. PubMed ID: 25048953
[TBL] [Abstract][Full Text] [Related]
20. [Synthetic glucocorticoid therapy in liver diseases].
Iino S; Hino K; Yasuda K
Nihon Rinsho; 1994 Mar; 52(3):719-27. PubMed ID: 8164373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
